Unknown

Dataset Information

0

Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report

ABSTRACT:

SUBMITTER: Sasaki A 

PROVIDER: S-EPMC12371464 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
| S-EPMC10543966 | biostudies-literature
Unknown Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab.
| S-EPMC12479639 | biostudies-literature
Unknown Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.
| S-EPMC12715066 | biostudies-literature
Unknown Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
| S-EPMC9305579 | biostudies-literature
Unknown Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer.
| S-EPMC7219097 | biostudies-literature
Unknown Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer.
| S-EPMC5427576 | biostudies-literature
Unknown Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
| S-EPMC9994048 | biostudies-literature
Unknown Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
| S-EPMC10024138 | biostudies-literature
Unknown Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas.
| S-EPMC7577914 | biostudies-literature
Unknown Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.
| S-EPMC8797704 | biostudies-literature